ClinicalTrials.gg

Program

AOC 1020

A development code. Also written as “AOC-1020”.

In Novartis's pipeline, siRNA DUX4 knockdown. Its studies are mostly in Muscular Dystrophy, Facioscapulohumeral, led by Novartis.

Furthest: phase 3, since Jun 13, 20253 company-led studies, 2 open or runningNext primary completion: May 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis32 open or runningphase 3since Jun 13, 2025Feb 17, 2023May 2028phase 3 · NCT07038200
  • Named in Novartis’s own pipeline as DWH213 (del-brax), phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2023First study: phase 2 study in Muscular Dystrophy, FacioscapulohumeralFirst studyNCT05747924 · 90 enrolled · United States, Canada, United Kingdom
  2. Aug 7, 2024Phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT06547216 · 84 enrolled · United States, Canada, United Kingdom
  3. Jun 13, 2025Phase 3 study in Muscular Dystrophy, FacioscapulohumeralNCT07038200 · 200 planned · United States, Canada, Denmark and more

Ahead

  1. May 2028Primary completion: phase 3 study in Muscular Dystrophy, FacioscapulohumeralNCT07038200
  2. Apr 2030Primary completion: phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT06547216

TargetBeta

“siRNA DUX4 knockdown”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07038200Muscular Dystrophy, Facioscapulohumeral · United States, Canada, Denmark and more3RecruitingMay 2028200
NCT06547216Muscular Dystrophy, Facioscapulohumeral · United States, Canada, United Kingdom2Active, not recruitingApr 203084
NCT05747924Muscular Dystrophy, Facioscapulohumeral · United States, Canada, United Kingdom2CompletedMar 18, 202690

How it is read

Names in the registry

  • “AOC 1020”, 2 entries
  • “AOC-1020”, 1 entry

Codes read as this program: AOC1020.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.